Genetic susceptibility to cancer from exogenous and endogenous exposures

Journal of Cellular Biochemistry

Volumn 63, Issue SUPPL. 25, 1996, Pages 15-22

  Feigelson, Heather Spencer ^a   Ross, Ronald K ^a   Yu, Mimi C ^a   Coetzee, Gerhard A ^a   Reichardt, Juergen K V ^a   Henderson, Brian E ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

bladder cancer; breast cancer; ethnicity; polymorphism prostate cancer

Indexed keywords

ASBESTOS; CYTOCHROME P450; ESTROGEN RECEPTOR; STEROID 5ALPHA REDUCTASE; TESTOSTERONE 17BETA DEHYDROGENASE; 3(17) HYDROXYSTEROID DEHYDROGENASE; 3(17)-HYDROXYSTEROID DEHYDROGENASE; ANDROGEN RECEPTOR; CHOLESTENONE 5ALPHA REDUCTASE; HYDROXYSTEROID DEHYDROGENASE; OXIDOREDUCTASE; STEROID 17ALPHA MONOOXYGENASE;

ADULT; BLADDER CANCER; BREAST CANCER; CANCER RISK; CANCER SUSCEPTIBILITY; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MOLECULAR BIOLOGY; POPULATION RISK; PRIORITY JOURNAL; PROSTATE CANCER; RECEPTOR GENE; REVIEW; TOBACCO; BLADDER TUMOR; BREAST TUMOR; CARCINOGEN TESTING; ENZYMOLOGY; FEMALE; GENETIC PREDISPOSITION; GENETICS; PROSTATE TUMOR;

NICOTIANA TABACUM;

ADULT; BREAST NEOPLASMS; CARCINOGENICITY TESTS; CHOLESTENONE 5 ALPHA-REDUCTASE; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYDROXYSTEROID DEHYDROGENASES; MALE; OXIDOREDUCTASES; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; STEROID 17-ALPHA-HYDROXYLASE; URINARY BLADDER NEOPLASMS;

EID: 0030329476     PISSN: 07302312     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-4644(1996)25+<15::AID-JCB2>3.0.CO;2-5     Document Type: Review

References (48)

1. Henderson BE, Ross RK, Pike MC (1991): Toward the primary prevention of cancer. Science 254:1131-1138.
2. Henderson BE, Ross RK, Pike MC, Casagrande JT (1982): Endogenous hormones as a major factor in human cancer. Cancer Res 42:3232-3239.
3. Henderson BE, Ross RK, Pike MC (1993): Hormonal chemoprevention of cancer in women. Science 259:633-638.
4. Vineis P (1992): Epidemiological models of carcinogenesis: The example of bladder cancer. Cancer Epidemiol Biomarkers Prev 1:149-153.
5. Yu MC, Skipper PL, Taghizadeh K, Tannenbaum SR, Chan KK, Henderson BE, Ross RK (1994): Acetylator phenotype, aminobiphenyl-hemoglobin adduct levels, and bladder cancer risk in white, black, and Asian men in Los Angeles, California. J Natl Cancer Inst 86:712-716.
6. Badawi AF, Hirvonen A, Bell DA, Lang NP, Kadlubar FF (1995): Role of aromatic amine acetyltransferases, NAT1 and NAT2, in carcinogen-DNA adduct formation in the human urinary bladder. Cancer Res 55:5230-5237.
7. Yu MC, Ross RK, Chan KK, Henderson BE, Skipper PL, Tannenbaum SR, Coetzee GA (1995): Glutathione S-transferase M1 genotype affects aminobiphenyl-hemoglobin adduct levels in White, Black, and Asian smokers and nonsmokers. Cancer Epidemiol Biomarkers Prev 4:861-864.
8. London SJ, Daly AK, Cooper J, Navidi WC, Carpenter CL, Idle JR (1995): Polymorphism of glutathione S-transferase M1 and lung cancer risk among African-Americans and Caucasians in Los Angeles County, California. J Natl Cancer Inst 87:1246-1253.
9. Lang NP, Butler MA, Massengill J, Lawson M, Stotts RC, Hauer-Jensen M, Kadlubar FF (1994): Rapid metabolic phenotypes for acetyltransferase and cytochrome P4501A2 and putative exposure to food-borne heterocyclic amines increase the risk for colorectal cancer or polyps. Cancer Epidemiol Biomarkers Prev 3:675-682.
10. 1. Proc Natl Acad Sci U S A 92:2384-2387.
11. Doll R, Peto R (1981): The causes of cancer: Quantitative estimates of avoidable risks of cancer in the United States today J Natl Cancer Inst 66:1191-1308.
12. PA (P-4501A2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proc Natl Acad Sci U S A 86:7696-7700.
13. Kalow W, Tang BK (1991): Caffeine as a metabolic probe: Exploration of the enzyme-inducing effect of cigarette smoking. Clin Pharmacol Ther 49:44-48.
14. Bryant MS, Vineis P, Skipper PL, Tannenbaum SR (1988): Hemoglobin adducts of aromatic amines: Associations with smoking status and type of tobacco. Proc Natl Acad Sci U S A 85:9788-9791.
15. Bell DA, Taylor JA, Butler MA, Stephens EA, Wiest J, Brubaker LH, Kadlubar FF, Lucier GW (1993): Genotype/phenotype discordance for human arylamine N-acetyltransferase (NAT2) reveals a new slow-acetylator allele common in African-Americans. Carcinogenesis 14:1689-1692.
16. Ross RK, Jones PA, Yu MC (1996): Bladder cancer epidemiology and pathogenesis. Sem Oncol 23:536-545.
17. Kirlin WG, Trinidad A, Yerokun T, Ogolla F, Ferguson RJ, Andrews AF, Brady PK, Hein DW (1989): Polymorphic expression of acetyl coenzyme A-dependent arylamine N-acetyltransferase and acetyl coenzyme A-dependent O-acetyltransferase-mediated activation of N-hydroxyarylamines by human bladder cytosols. Cancer Res 49:2448-2454.
18. Frederickson SM, Messing EM, Reznikoff CA, Swaminathan S (1994): Relationship between in vivo acetylator pheaotypes and cytosolic N-acetyltransferase and O-acetyltransferase activities in human urothelial cells. Cancer Epidemiol Biomarkers Prev 3:25-32.
19. Board P, Coggan M, Johnston P, Ross V, Suzuki T, Webb G (1990): Genetic heterogeneity of the human glutathione transferases: A complex of gene families. Pharmacol Ther 48:357-369.
20. Bell DA, Taylor JA, Paulson DF, Robertson CN, Mohler JL, Lucier GW (1993): Genetic risk and carcinogen exposure: A common inherited defect of the carcinogenmetabolism gene glutathione S-transferase M1 (GSTM1) that increases susceptibility to bladder cancer. J Natl Cancer Inst 85:1159-1164.
21. Ross RK: Prostate cancer. In Schottenfeld D, Fraumeni J (eds): "Cancer Epidemology and Prevention." Oxford: Oxford University Press, in press.
22. Ross RK, Bernstein L, Judd H, Hanisch R, Pike MC, Henderson BE (1986): Serum testosterone levels in young black and white men. J Natl Cancer Inst 76:45-48.
23. Ross RK, Bernstein L, Lobo RA, Shimizu H, Stanczyk FZ, Pike MC, Henderson BE (1992): 5-α-reductase activity and risk of prostate cancer among Japanese and U.S. white and black males. Lancet 339: 887-889.
24. Thigpen AE, Davis DL, Gautier T, Imperato-McGinley J, Russell W (1992): The molecular basis of steroid 5-alpha- reductase deficiency in a large Dominican kindren. N Engl J Med 327:1216-1219.
25. Davis DL, Russell DW (1993): Unusual length polymorphisms in human steroid 5-α-reductase type 2 gene (SRD5A2). Hum Mol Genet 2:820.
26. Reichardt JKV, Makridakis N, Henderson BE, Yu MC, Pike MC, Ross RK (1995): Genetic variability of the human SRD5A2 gene: Implications for prostate cancer risk. Cancer Res 55:3973-3975.
27. Brentano ST, Picado-Leonard J, Mellon SH, Moore CCD, Miller WL (1990): Tissue-specific, cyclic adenosine 3′,5′-monophosphate-induced, and phorbol esterrepressed transcription from the human P450c17 promoter in mouse cells. Mol Endocrinol 4:1972-1979.
28. Carey AH, Waterworth D, Patel K, White D, Little J, Novelli P, Franks S, Williamson R (1994): Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. Hum Mol Genet 3:1873-1876.
29. Kadonaga JT, Jones KA, Tjian R (1986): Promoter-specific activation of RNA polymerase II transcription by SpI. Trends Biochem Sci 11:20-23.
30. Jenster G, Van der Korput HAGM, Van Vroonhoven C, Van der Kwast TH, Trapman J, Brinkinann AO (1991): Domains of human androgen receptor involved in steroid binding, transcriptional activation, and subcellular localization. Mol Endocrinol 5:1396-1404.
31. La Spada AR, Wilson EM, Lubahn DB, Harding AE, Fischback KH (1991): Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 352:77-79.
32. Mhatre AN, Trifiro MA, Kaufman M, Kazemi-Esfarjani P, Figlewicz D, Rouleau G, Pinsky L (1993): Reduced transcriptional regulatory competence of the androgen receptor in X-linked spinal and bulbar muscular atrophy. Nature Genet 5:184-188.
33. Edwards A, Hammond HA, Jin L, Caskey CT, Chakraborty R (1992): Genetic variation at five trimeric and tandem repeat loci in four human population groups. Genomics 12:241-253.
34. Irvine RA, Yu MC, Ross RK, Coetzee GA (1995): The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer. Cancer Res 55:1937-1940.
35. Henderson BE, Gerkins V, Rosario I, Casagrande JT, Pike MC (1975): Elevated serum levels of estrogen and prolactin in daughters of patients with breast cancer. New Engl J Med 293:790-795.
36. Bernstein L, Yuan JM, Ross RK, Pike MC, Hanisch R, Lobo R, Stanczyk F, Gao YT, Henderson BE (1990): Serum hormone levels in premenopausal Chinese women in Shanghai and white women in Los Angeles: Results from two breast cancer case-control studies. Cancer Causes Control 1:51-58.
37. Shimizu H, Ross RK, Berstein L, Pike MC, Henderson BE (1990). Serum oestrogen levels in postmenopausal women: Comparison of American whites and Japanese in Japan. Brit J Cancer 62:451-453.
38. England P, Skinner L, Cottrell K, Sellwood RA (1974): Serum oestradiol-17β in women with benign and malignant breast disease. Brit J Cancer 30:571-576.
39. Poutanen M, Isomaa V, Lehto V-P, Vihko R (1992): Immunological analysis of 17β-hydroxysteroid dehydrogenase in benign and malignant human breast tissue. Int J Cancer 50:386-390.
40. Normand T, Narod S, Labrie F, Simard J (1993): Detection of polymorphisms in the estradiol 17β-hydroxysteroid dehydrogenase II gene at the EDH17B2 locus on 17q11-q21. Hum Mol Genet 2:479-483.
41. Mannermaa A, Peltoketo H, Winqvist R, Ponder BAJ, Kiviniemi H, Easton DF, Poutanen M, Isomaa V, Vihko R (1994): Human familial and sporadic breast cancer: Analysis of the coding regions of the 17β-hydroxysteroid dehydrogenase 2 gene (EDH17B2) using a single-strand conformation polymorphism assay. Hum Genet 93:319-324.
42. Puranen TJ, Poutanen MH, Peltoketo HE, Vihko PT, Vihko RK (1994): Site-directed mutagenesis of the putative active site of human 17β-hydroxysteroid dehydrogenase type 1. Biochem J 304:289-293.
43. Peltoketo H, Yunshang P, Mannermaa A, Pander BAJ, Isomaa V, Poutanen M, Winqvist R, Vihko R (1994). A point mutation in the putative TATA box, detected in nondiseased individuals and patients with hereditary breast cancer, decreases promoter activity of the 17β-hydroxysteroid dehydrogenase type 1 gene 2 (EHD17B2) in vitro. Genomics 23:250-252.
44. Castagnoli A, Maestri I, Bernardi F, del Senno L (1987): PvuII RFLP inside the human estrogen receptor gene. Nucleic Acids Res 15 866.
45. Garcia T, Sanchez M, Cox JL, Shaw PA, Ross JBA, Lehrer S, Schachter B (1989): Identification of a variant form of the human estrogen receptor with an amino acid replacement. Nuc Acids Res 17:8364.
46. Andersen TI, Heimdal KR, Skrede M, Tveit K, Berg K, Borresen A-L (1994): Oestrogen receptor (ESR) polymorphisms and breast cancer susceptibility. Hum Genet 94:665-670.
47. del Senno L, Aguiari GL, Piva R (1992): Dinucleotide repeat polymorphism in the human estrogen receptor (ESR) gene. Hum Mol Genet 1:354.
48. Keaveney M, Klug J, Dawson MT, Nestor PV, Neilan JG, Forde RC, Gannon F (1991): Evidence for a previously unidentified upstream exon in the human oestrogen receptor gene. J Mol Endocrinol 6:111-115.